Relationship	O
between	O
genetic	B:C0032529
polymorphisms	I:C0032529
of	O
methylenetetrahydrofolate	B:C0066357
reductase	I:C0066357
and	O
breast	B:C0006142
cancer	I:C0006142
chemotherapy	B:C3665472
response	B:C0521982
.	O

Activity	B:C1151783
of	I:C1151783
methylenetetrahydrofolate	I:C1151783
reductase	I:C1151783
(	O
methylenetetrahydrofolate	B:C0066357
reductase	I:C0066357
)	O
,	O
an	O
enzyme	B:C0014442
involved	O
in	O
folate	B:C1157079
metabolism	I:C1157079
,	O
is	O
influenced	O
by	O
mutations	B:C0596611
in	O
the	O
corresponding	O
gene	B:C0017337
,	O
contributing	O
to	O
a	O
decrease	O
in	O
5,10	B:C0048858
-	I:C0048858
MTHF	I:C0048858
.	O

Due	O
to	O
such	O
polymorphisms	B:C0032529
,	O
individuals	B:C0237401
differ	O
in	O
MTHFR	B:C1151783
enzyme	I:C1151783
activity	I:C1151783
and	O
plasma	B:C0427425
folate	I:C0427425
levels	I:C0427425
.	O

We	O
investigated	O
the	O
relationship	O
between	O
two	O
common	O
methylenetetrahydrofolate	B:C0919427
reductase	I:C0919427
polymorphisms	B:C0032529
(	O
C677T	B:C0017337
and	O
A1298C	B:C0017337
)	O
and	O
breast	B:C0006142
cancer	I:C0006142
(	O
breast	B:C0006142
cancer	I:C0006142
)	O
chemotherapy	B:C3665472
response	B:C0521982
.	O

From	O
February	O
2013	O
to	O
January	O
2016	O
,	O
148	O
advanced	O
breast	B:C0006142
cancer	I:C0006142
patients	O
at	O
the	O
Center	B:C0019994
Hospital	I:C0019994
of	O
Cangzhou	O
were	O
enrolled	O
and	O
treated	O
with	O
six	O
different	O
chemotherapy	B:C0392920
regimens	I:C0392920
.	O

Subjects	B:C0080105
were	O
genotyped	O
using	O
polymerase	B:C0032520
chain	I:C0032520
reaction	I:C0032520
-	O
restriction	B:C0035268
fragment	I:C0035268
length	I:C0035268
polymorphism	I:C0035268
.	O

Forty	O
-	O
one	O
(	O
27.7	O
%	O
)	O
,	O
70	O
(	O
47.3	O
%	O
)	O
,	O
and	O
37	O
(	O
25.0	O
%	O
)	O
patients	O
carried	O
the	O
C/C	O
,	O
C/T	O
,	O
and	O
T/T	O
C677T	O
genotypes	O
,	O
respectively	O
;	O
101	O
(	O
68.2	O
%	O
)	O
,	O
42	O
(	O
28.4	O
%	O
)	O
,	O
and	O
5	O
(	O
3.4	O
%	O
)	O
had	O
the	O
A/A	O
,	O
A/C	O
,	O
and	O
C/C	O
genotypes	O
of	O
A1298C	B:C0017337
,	O
respectively	O
.	O

Total	O
chemotherapy	B:C3665472
efficacy	O
was	O
66.9	O
%	O
(	O
99/148	O
)	O
,	O
with	O
7	O
(	O
4.7	O
%	O
)	O
,	O
92	O
(	O
62.2	O
%	O
)	O
,	O
36	O
(	O
24.3	O
%	O
)	O
,	O
and	O
13	O
(	O
8.8	O
%	O
)	O
cases	O
showing	O
complete	O
response	B:C0521982
,	O
partial	O
response	B:C0521982
,	O
no	B:C0442739
change	I:C0442739
,	O
and	O
progressive	B:C0677932
disease	I:C0677932
,	O
respectively	O
.	O

Chemotherapy	B:C0392920
regimens	I:C0392920
did	O
not	O
differ	O
in	O
effectiveness	O
(	O
P	O
>	O
0.05	O
)	O
.	O

Efficacy	O
rates	O
associated	O
with	O
C677T	O
C/C	O
,	O
C/T	O
,	O
and	O
T/T	O
genotypes	O
were	O
58.5	O
,	O
58.6	O
,	O
and	O
91.9	O
%	O
,	O
respectively	O
,	O
with	O
T/T	O
carriers	B:C0007294
exhibiting	O
significantly	O
better	O
responses	B:C0521982
than	O
the	O
C/C	O
(	O
P	O
<	O
0.05	O
)	O
and	O
C/T	O
groups	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Effectiveness	O
among	O
A1298C	B:C0017337
A/A	O
,	O
A/C	O
,	O
and	O
C/C	O
carriers	B:C0007294
was	O
70.6	O
,	O
64.3	O
,	O
and	O
0.0	O
%	O
,	O
respectively	O
,	O
but	O
no	O
difference	O
was	O
established	O
between	O
these	O
genotypes	O
in	O
this	O
regard	O
(	O
P	O
>	O
0.05	O
)	O
.	O

The	O
methylenetetrahydrofolate	B:C0919427
reductase	I:C0919427
C677T	O
genotype	O
may	O
be	O
associated	O
with	O
breast	B:C0006142
cancer	I:C0006142
chemotherapy	B:C3665472
response	B:C0521982
,	O
and	O
could	O
be	O
of	O
great	O
value	O
in	O
guiding	B:C0220845
individualized	O
treatment	B:C0087111
for	O
this	O
disease	B:C0012634
.	O

